Wehring Heidi J, Thedford Sheryl, Koola Maju, Kelly Deanna L
Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA.
J Cent Nerv Syst Dis. 2011 Jun 1;2011(3):107-123. doi: 10.4137/JCNSD.S4091.
Olanzapine long acting injection has joined risperidone and paliperidone as the second generation long acting antipsychotic injection options for treatment of patients with schizophrenia. Long acting injections are important alternatives to oral medications for patients who have difficulty adhering to daily or multiple daily medication administrations, yet may be underutilized or not well understood. Patient perceptions, adherence, and preferences are important issues for health care providers to address when discussing treatment options with their patients. Reviewed here are overall patient and health care provider attitudes and perceptions regarding long acting injections and the details of olanzapine long acting injectable, the newest agent, and how it will fit in the marketplace. In addition, efficacy, safety, dosing and use data regarding this newest long acting agent are reviewed and compared to other available long acting agents.
奥氮平长效注射剂已与利培酮和帕利哌酮一起，成为治疗精神分裂症患者的第二代长效抗精神病注射剂选择。对于难以坚持每日或每日多次服药的患者，长效注射剂是口服药物的重要替代方案，但可能未得到充分利用或未被充分理解。在与患者讨论治疗方案时，患者的认知、依从性和偏好是医疗保健提供者需要解决的重要问题。本文回顾了患者和医疗保健提供者对长效注射剂的总体态度和认知，以及最新药物奥氮平长效注射剂的详细情况，及其在市场中的定位。此外，还对这种最新长效药物的疗效、安全性、给药和使用数据进行了回顾，并与其他可用的长效药物进行了比较。
